603087 Stock Overview
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and commercialization insulin analogues primarily in China.
Gan & Lee Pharmaceuticals. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CN¥33.10|
|52 Week High||CN¥83.38|
|52 Week Low||CN¥32.88|
|1 Month Change||-10.10%|
|3 Month Change||-29.26%|
|1 Year Change||-57.46%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-49.18%|
Recent News & Updates
|603087||CN Biotechs||CN Market|
Return vs Industry: 603087 underperformed the CN Biotechs industry which returned -35.5% over the past year.
Return vs Market: 603087 underperformed the CN Market which returned -18.6% over the past year.
|603087 Average Weekly Movement||4.9%|
|Biotechs Industry Average Movement||4.8%|
|Market Average Movement||5.8%|
|10% most volatile stocks in CN Market||9.3%|
|10% least volatile stocks in CN Market||3.7%|
Stable Share Price: 603087 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 603087's weekly volatility (5%) has been stable over the past year.
About the Company
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and commercialization insulin analogues primarily in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro; Raplin, an insulin aspart injection; Raplin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection, as well as medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd.
Gan & Lee Pharmaceuticals. Fundamentals Summary
|603087 fundamental statistics|
Is 603087 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|603087 income statement (TTM)|
|Cost of Revenue||CN¥380.96m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||1.57|
|Net Profit Margin||29.70%|
How did 603087 perform over the long term?See historical performance and comparison